Hospital
VHS Acquisition Subsidiary Number 9 INC
VHS Acquisition Subsidiary Number 9 INC was paid $58.88M by Medicaid between Jan 2018 and Dec 2024, across 337 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoVHS ACQUISITION SUBSIDIARY NUMBER 9 INC
FRAMINGHAM, MA 01702
FRAMINGHAM, MA 01702
33aNPI1740252592assigned 02/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$58.88M
24GClaims1,451,948
24DCodes billed337
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#22 of 66
Median peer was paid$29.11M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 293,154 | $11.95M | |
| 2019 | 259,137 | $9.89M | |
| 2020 | 189,046 | $6.62M | |
| 2021 | 205,652 | $7.60M | |
| 2022 | 189,988 | $8.19M | |
| 2023 | 170,347 | $7.83M | |
| 2024incomplete | 144,624 | $6.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 59,141 | 54,324 | $8.80M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 43,245 | 39,629 | $6.92M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.7% | 17,106 | 15,053 | $5.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.9% | 27,200 | 24,279 | $4.62M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4.8% | 22,827 | 20,809 | $2.84M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.1% | 4,241 | 4,059 | $2.43M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.8% | 18,731 | 16,448 | $2.21M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 29,316 | 9,399 | $1.32M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.0% | 10,311 | 9,520 | $1.16M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 7,805 | 7,433 | $1.05M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 6,058 | 5,680 | $1.04M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 8,825 | 6,894 | $994K |
325 more codes
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.6% | 1,382 | $940K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 8,237 | $933K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.4% | 6,521 | $801K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 6,608 | $772K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 5,097 | $626K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 705 | $567K |
| 59025 | Fetal non-stress test | <1% | 2,520 | $549K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 17,593 | $519K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,541 | $514K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,221 | $452K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,699 | $428K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,406 | $425K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,947 | $408K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,850 | $383K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 78,525 | $381K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,723 | $375K |
| 76642 | <1% | 4,459 | $349K | |
| 93976 | <1% | 2,548 | $348K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 11,003 | $337K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,266 | $335K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 21,174 | $329K |
| G0378 | Hospital observation service, per hour | <1% | 6,312 | $300K |
| 76830 | Ultrasound, transvaginal | <1% | 3,559 | $287K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,639 | $281K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 10,054 | $275K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,575 | $245K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 16,919 | $240K |
| 80053 | Comprehensive metabolic panel | <1% | 62,531 | $228K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,200 | $200K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,093 | $197K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,216 | $194K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,390 | $192K |
| 97035 | <1% | 4,886 | $177K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 662 | $171K |
| ATP14 | <1% | 18,359 | $153K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,097 | $149K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,422 | $146K |
| 97162 | <1% | 3,253 | $146K | |
| 93971 | <1% | 906 | $137K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,910 | $131K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,395 | $130K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,387 | $125K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,750 | $123K |
| 92552 | <1% | 1,389 | $116K | |
| 84484 | <1% | 18,279 | $109K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,058 | $105K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 18,791 | $103K |
| 81025 | <1% | 14,182 | $91K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,326 | $90K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,160 | $89K |
| 87081 | <1% | 10,802 | $88K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,001 | $88K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 28,388 | $86K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 414 | $85K |
| 12001 | <1% | 385 | $81K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 502 | $80K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,932 | $78K |
| 80061 | Lipid panel | <1% | 22,830 | $77K |
| 85027 | <1% | 18,268 | $76K | |
| 76801 | <1% | 1,620 | $76K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,837 | $76K |
| 73562 | <1% | 3,599 | $72K | |
| 80050 | General health panel | <1% | 1,861 | $70K |
| 73630 | <1% | 3,611 | $68K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,155 | $67K |
| 73610 | <1% | 3,064 | $66K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 8,552 | $66K |
| 84702 | <1% | 5,116 | $65K | |
| 83690 | <1% | 12,025 | $61K | |
| ATP08 | <1% | 9,067 | $59K | |
| 82728 | <1% | 6,306 | $56K | |
| 73030 | <1% | 2,778 | $55K | |
| 82607 | <1% | 5,715 | $53K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,873 | $52K |
| 88342 | <1% | 4,657 | $51K | |
| 90715 | <1% | 2,015 | $50K | |
| 71250 | <1% | 838 | $48K | |
| 83655 | <1% | 4,178 | $47K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,001 | $47K |
| ATP15 | <1% | 5,271 | $46K | |
| 81001 | <1% | 19,444 | $45K | |
| S9485 | Crisis intervention mental health services, per diem | <1% | 148 | $44K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,709 | $41K |
| 72100 | <1% | 2,370 | $41K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,420 | $41K |
| 76536 | <1% | 354 | $40K | |
| 86780 | <1% | 3,654 | $39K | |
| 83880 | <1% | 2,520 | $37K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 945 | $36K |
| 87186 | <1% | 5,465 | $36K | |
| 77062 | <1% | 669 | $36K | |
| 83735 | <1% | 10,065 | $34K | |
| 87631 | <1% | 287 | $34K | |
| 97161 | <1% | 715 | $34K | |
| 77080 | <1% | 571 | $33K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,171 | $33K |
| ATP17 | <1% | 4,932 | $32K | |
| 84703 | <1% | 5,590 | $31K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,708 | $31K |
| 70486 | <1% | 227 | $31K | |
| 73130 | <1% | 1,762 | $30K | |
| 77061 | <1% | 570 | $30K | |
| 76770 | <1% | 198 | $29K | |
| 74018 | <1% | 976 | $29K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,170 | $28K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 186 | $27K |
| 87905 | <1% | 3,097 | $27K | |
| 86850 | <1% | 3,850 | $27K | |
| 87808 | <1% | 2,904 | $26K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 410 | $26K |
| 86140 | <1% | 5,901 | $26K | |
| 82746 | <1% | 2,778 | $25K | |
| 86803 | <1% | 2,341 | $25K | |
| 87070 | <1% | 3,372 | $25K | |
| 81003 | <1% | 14,760 | $25K | |
| 83550 | <1% | 5,068 | $24K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 28 | $24K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,754 | $23K |
| 86703 | <1% | 2,417 | $22K | |
| 83540 | <1% | 5,650 | $21K | |
| 84439 | <1% | 4,309 | $21K | |
| 97113 | <1% | 323 | $21K | |
| 85379 | <1% | 2,875 | $20K | |
| 82570 | <1% | 6,614 | $20K | |
| 82553 | <1% | 2,952 | $19K | |
| 87340 | <1% | 2,062 | $19K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 13 | $18K |
| 87040 | <1% | 2,604 | $18K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 57,825 | $18K |
| 96367 | <1% | 308 | $18K | |
| 87102 | <1% | 2,734 | $17K | |
| 85610 | <1% | 7,555 | $17K | |
| 82550 | <1% | 13,878 | $16K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,914 | $14K |
| 87536 | <1% | 510 | $14K | |
| 86900 | <1% | 5,417 | $14K | |
| 73110 | <1% | 908 | $14K | |
| 86618 | <1% | 871 | $14K | |
| 82043 | <1% | 4,892 | $14K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 480 | $13K |
| 86901 | <1% | 5,397 | $13K | |
| 88304 | <1% | 1,294 | $13K | |
| 84153 | <1% | 958 | $13K | |
| 87077 | <1% | 2,419 | $13K | |
| 73502 | <1% | 899 | $13K | |
| 87807 | <1% | 850 | $13K | |
| 12002 | <1% | 54 | $12K | |
| 10060 | <1% | 99 | $12K | |
| 80076 | <1% | 4,140 | $11K | |
| 97803 | <1% | 209 | $11K | |
| 83605 | <1% | 2,233 | $11K | |
| 85651 | <1% | 3,789 | $11K | |
| 73564 | <1% | 374 | $11K | |
| 86255 | <1% | 792 | $10K | |
| 82784 | <1% | 1,412 | $10K | |
| 73140 | <1% | 572 | $9K | |
| 86706 | <1% | 959 | $9K | |
| 86038 | <1% | 916 | $9K | |
| 90674 | <1% | 455 | $9K | |
| 85730 | <1% | 2,815 | $8K | |
| 94729 | <1% | 323 | $8K | |
| 94375 | <1% | 148 | $8K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,628 | $8K |
| 93017 | <1% | 58 | $7K | |
| 87147 | <1% | 1,236 | $7K | |
| 82962 | <1% | 18,866 | $7K | |
| 80074 | <1% | 227 | $7K | |
| 74019 | <1% | 777 | $7K | |
| 86480 | <1% | 179 | $7K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 48 | $7K |
| 97032 | <1% | 211 | $6K | |
| 87088 | <1% | 1,020 | $6K | |
| 90686 | <1% | 415 | $6K | |
| 97166 | <1% | 119 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 172 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,986 | $6K |
| 96376 | <1% | 2,039 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,005 | $6K |
| 97602 | <1% | 39 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,073 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 148 | $5K |
| 86762 | <1% | 344 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,365 | $5K |
| ATP09 | <1% | 751 | $5K | |
| 84460 | <1% | 3,838 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,063 | $5K |
| ATP03 | <1% | 1,877 | $4K | |
| 82565 | <1% | 1,540 | $4K | |
| 76870 | <1% | 38 | $4K | |
| 83970 | <1% | 368 | $4K | |
| ATP11 | <1% | 701 | $4K | |
| 83516 | <1% | 368 | $4K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 299 | $4K |
| 86787 | <1% | 287 | $4K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 65 | $4K |
| 81002 | <1% | 1,499 | $4K | |
| ATP18 | <1% | 644 | $4K | |
| 84450 | <1% | 2,398 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,560 | $3K |
| 76775 | <1% | 26 | $3K | |
| 71101 | <1% | 197 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,766 | $3K |
| ATP04 | <1% | 515 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,697 | $3K |
| 84550 | <1% | 1,899 | $3K | |
| 29125 | <1% | 24 | $3K | |
| 84403 | <1% | 155 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 382 | $3K |
| 87205 | <1% | 1,032 | $3K | |
| 97163 | <1% | 74 | $3K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 252 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,521 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,782 | $2K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 29 | $2K |
| 84156 | <1% | 830 | $2K | |
| ATP07 | <1% | 421 | $2K | |
| 11721 | <1% | 94 | $2K | |
| 82803 | <1% | 204 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,880 | $2K |
| 94664 | <1% | 482 | $1K | |
| 88142 | <1% | 514 | $1K | |
| 82150 | <1% | 310 | $1K | |
| 80164 | <1% | 343 | $1K | |
| 93970 | <1% | 13 | $1K | |
| ATP13 | <1% | 173 | $1K | |
| A9270 | Non-covered item or service | <1% | 10,119 | $1K |
| ATP12 | <1% | 144 | $1K | |
| 83615 | <1% | 865 | $1K | |
| 87338 | <1% | 130 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,713 | $1K |
| 72050 | <1% | 69 | $1K | |
| 80305 | <1% | 246 | $1K | |
| 86431 | <1% | 138 | $942.59 | |
| 87046 | <1% | 162 | $829.92 | |
| 84520 | <1% | 407 | $780.10 | |
| 87045 | <1% | 151 | $772.32 | |
| 85018 | <1% | 435 | $716.75 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 15 | $655.46 |
| 84146 | <1% | 78 | $649.65 | |
| ATP02 | <1% | 200 | $646.56 | |
| J1815 | Injection, insulin, per 5 units | <1% | 44 | $620.44 |
| 83721 | <1% | 150 | $612.92 | |
| ATP10 | <1% | 176 | $600.32 | |
| 81015 | <1% | 352 | $576.29 | |
| 84100 | <1% | 2,691 | $557.34 | |
| 82950 | <1% | 81 | $481.34 | |
| 83001 | <1% | 41 | $479.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 78 | $465.33 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 280 | $465.33 |
| 73080 | <1% | 68 | $435.34 | |
| 83002 | <1% | 27 | $414.19 | |
| 86360 | <1% | 68 | $393.93 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 210 | $382.43 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 24 | $369.49 |
| 86364 | <1% | 56 | $361.93 | |
| 87207 | <1% | 103 | $345.34 | |
| 86359 | <1% | 68 | $324.23 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 297 | $310.22 |
| 80178 | <1% | 162 | $302.95 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,185 | $295.69 |
| 99188 | <1% | 13 | $284.90 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,263 | $272.81 |
| 86617 | <1% | 54 | $271.66 | |
| 87272 | <1% | 47 | $268.56 | |
| 87015 | <1% | 63 | $267.06 | |
| 87269 | <1% | 45 | $261.72 | |
| 83021 | <1% | 12 | $250.30 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 120 | $247.80 |
| 85014 | <1% | 97 | $211.48 | |
| 73590 | <1% | 54 | $187.80 | |
| ATP05 | <1% | 30 | $177.32 | |
| 86376 | <1% | 17 | $165.11 | |
| ATP16 | <1% | 20 | $141.57 | |
| 85045 | <1% | 110 | $131.92 | |
| D1206 | Topical application of fluoride varnish | <1% | 175 | $118.44 |
| 85384 | <1% | 34 | $116.25 | |
| 86800 | <1% | 14 | $114.91 | |
| 86735 | <1% | 17 | $107.60 | |
| 84402 | <1% | 14 | $105.04 | |
| 86704 | <1% | 15 | $98.91 | |
| 85660 | <1% | 12 | $94.36 | |
| 86765 | <1% | 16 | $93.03 | |
| 86677 | <1% | 15 | $89.82 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 24 | $86.88 |
| 82248 | <1% | 62 | $81.34 | |
| 83010 | <1% | 14 | $80.29 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 125 | $71.13 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 67 | $62.00 |
| 86753 | <1% | 16 | $56.50 | |
| 84165 | <1% | 15 | $55.35 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 258 | $52.60 |
| 82247 | <1% | 129 | $49.85 | |
| 86334 | <1% | 14 | $46.08 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 74 | $39.70 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 44 | $28.83 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 75 | $27.63 |
| 74022 | <1% | 12 | $24.40 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 22 | $15.42 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 354 | $10.07 |
| 82947 | <1% | 58 | $8.10 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 15 | $3.16 |
| S0028 | Injection, famotidine, 20 mg | 0% | 705 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 119 | $0.00 |
| 99001 | 0% | 13 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 320 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 415 | $0.00 |
| 84145 | 0% | 111 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 25 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 39 | $0.00 |
| 99218 | 0% | 41 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 19 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 16 | $0.00 |
| C1769 | Guide wire | 0% | 236 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 2,262 | $0.00 |
| 80069 | 0% | 60 | $0.00 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 43 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 163 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 76 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 27 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 13 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 31 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 14 | $0.00 |
| 87467 | 0% | 50 | $0.00 | |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | 0% | 94 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCDONALD, ANDREW (CFO)